Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
4 hedge funds and large institutions have $33K invested in Lixte Biotechnology Warrants in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and closing their positions.
200% more capital invested
Capital invested by funds: $11K → $33K (+$22K)
100% more funds holding
Funds holding: 2 → 4 (+2)
0.99% more ownership
Funds ownership: 0.18% → 1.17% (+0.99%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$27K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$3.91K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$602 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
1
Empery Asset Management
New York
| $20K | +$27K | +105,263 | New |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $8K | +$3.91K | +15,269 | +85% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $3K | +$3.49K | +13,610 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $2K | +$602 | +2,350 | +38% |
|
LIXTW Hedge Fund Activity: Q1 2022 in Review
4 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q1 2022, worth a combined $33K — up 200% from $11K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LIXTW positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $27K.
- 4 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q1 2022, up from 2 in Q4 2021.
- Funds reported $33K of Lixte Biotechnology Warrants stock for Q1 2022, up 200% quarter-over-quarter.
- 2 funds opened new Lixte Biotechnology Warrants positions in Q1 2022 and 0 closed out, a net change of +2 holders.
- The largest Lixte Biotechnology Warrants buyer in Q1 2022 was Empery Asset Management, an estimated $27K added.
Based on aggregated 13F filings for Q1 2022.